AMP Horizons Series: Whole Genome Sequencing for Clinical Cancer Diagnostics


Cytogenetic evaluation of AML and MDS has been the mainstay of clinical risk assessment for over 40 years.  While effective for risk-stratification, cytogenetics requires the culture of live cells and provides limited resolution to resolve complex genomic events. Whole genome sequencing, WGS, is capable of unbiased genomic evaluation from DNA but has been considered too expensive and too complicated, for clinical use.  In this webinar we will discuss recent advances that have made WGS feasible in the clinical setting, how WGS data can be used for the comprehensive genomic assessment of AML and MDS patients, and how WGS could be implemented for the evaluation of other cancer types. 

Learning Objectives:

  • Describe how cytogenetics and molecular testing plays a role in the diagnosis and management of myeloid disorders such as AML.
  • Identify key barriers to using whole genome sequencing (WGS) in the clinical setting.
  • Describe benefits of WGS over conventional genomic testing in myeloid malignancies.
  • Identify other areas of molecular diagnostics where WGS could be applied.

Eric Duncavage, MD
Washington University School of Medicine

Nathanael G. Bailey, MD
Chair, T&E Committee
University of Pittsburgh Medical Center
Duration: 1 Hour
Level of Instruction: Basic
Recording Date: July 20, 2021

Continuing Education Credit Information

CME credit: 1.0
CMLE credit: 1.0 
Last day to claim credit:  March 20, 2024

Accreditation Statements
AMA PRA Category 1 Credit(s)
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.

The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity. 

Note: Join the AMP Family for discounted access to the most current educational resources!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.